TOKIWA-Bio Inc., which is developed gene therapy and regenerative medicine, announced that it secured a new capital of 330 million yen through third-party allotment of shares allocated to operating companies and venture capital. 　TOKIWA – Bio Inc. plans to utilize financing to accelerate the development of multiple programs based on Stealth RNA Vector, which is its own platform technology.